AstraZeneca (AZN.US) anti-PD-L1 monoclonal antibody approved for new indication in China for the treatment of small cell lung cancer.

According to the Tencent Finance APP, on June 4th, AstraZeneca (AZN.US) announced that the anti-PD-L1 monoclonal antibody durvalumab has been approved by the China National Medical Products Administration (NMPA) for a new indication, as a monotherapy for the treatment of adult patients with limited-stage small cell lung cancer (LS-SCLC) who have not progressed after receiving platinum-based chemotherapy. This approval is based on the positive results of the ADRIATIC phase 3 clinical trial. Previously, the data from the global ADRIATIC clinical trial was successfully published in the New England Journal of Medicine (NEJM); and the results of the Chinese cohort study have been presented at this year's European Lung Cancer Congress (ELCC).